Trial reportGut and liver2017
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.
Trial report in Gut and liver, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.PloS one · 2022Pooled it
- Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.Hepatology international · 2021Trial
- [Novel targets and drugs for the treatment of portal hypertension in liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Intestinal decontamination with rifaximin attenuates LSEC dysfunction and liver fibrosis in mice.PloS one · 2026Article
- Gut microbiome and its metabolites in liver cirrhosis: mechanisms and clinical implications.Frontiers in cellular and infection microbiology · 2025Review
- Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.Journal of gastroenterology · 2024Review
- Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy.Journal of clinical medicine · 2023Article
- Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota.Antibiotics (Basel, Switzerland) · 2023Review
- Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.Journal of clinical medicine · 2023Review
- Emerging Therapeutic Targets for Portal Hypertension.Current hepatology reports · 2023Review
- Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites.Medicina (Kaunas, Lithuania) · 2022Article
- [Cirrhotic portal hypertension reversal mechanism and its therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Current and investigational drugs in early clinical development for portal hypertension.Frontiers in medicine · 2022Review
- The Use of Rifaximin in Patients With Cirrhosis.Hepatology (Baltimore, Md.) · 2021Review
- The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.Hepatology international · 2021Article
- Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatology international · 2021Review
- Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.International journal of molecular sciences · 2020Review
- [Consensus on clinical application of hepatic venous pressure gradient in China (2018)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score.Journal of cachexia, sarcopenia and muscle · 2018Article
- Advances and challenges in cirrhosis and portal hypertension.BMC medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsNon-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to propranolol therapy can improve hepatic venous pressure gradient (HVPG) response.
methodsSixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint.
resultsCombination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047).
conclusionsRifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.